{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:30:15Z","timestamp":1778077815819,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-025-02043-6","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T06:47:29Z","timestamp":1763189249000},"page":"246-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity phenotypes and reversal of pharmacokinetic impact in anti-TNF\u2013treated immune-mediated diseases: a real-world study"],"prefix":"10.1007","volume":"48","author":[{"given":"Roc\u00edo","family":"Guzm\u00e1n-Laiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-7250","authenticated-orcid":false,"given":"Carles","family":"Iniesta-Naval\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"R\u00edos-Saor\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Rentero-Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Garcia-Masegosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"A\u00f1ez-Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Urbieta-Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"2043_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clim.2018.03.004","volume":"206","author":"KH Katsanos","year":"2019","unstructured":"Katsanos KH, Papamichael K, Feuerstein JD, et al. Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies. Clin Immunol. 2019;206:9\u201314.","journal-title":"Clin Immunol"},{"key":"2043_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis. 2018;77:175\u201387.","journal-title":"Ann Rheum Dis"},{"key":"2043_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/FTD.0000000000000571","volume":"41","author":"E Dreesen","year":"2019","unstructured":"Dreesen E, Gils A. Pharmacodynamic monitoring of biological therapies in chronic inflammatory diseases. Ther Drug Monit. 2019;41:131\u201341.","journal-title":"Ther Drug Monit"},{"key":"2043_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","volume":"9","author":"N Chanchlani","year":"2024","unstructured":"Chanchlani N, Lin S, Bewshea C, et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterol Hepatol. 2024;9:521\u201338.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2043_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","volume":"17","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655\u201368.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2043_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/1751-2980.12698","volume":"20","author":"QW Zhang","year":"2019","unstructured":"Zhang QW, Shen J, Zheng Q, et al. Loss of response to scheduled infliximab therapy for Crohn\u2019s disease in adults: a systematic review and meta-analysis. J Dig Dis. 2019;20:65\u201372.","journal-title":"J Dig Dis"},{"key":"2043_CR7","first-page":"764518","volume":"2013","author":"A Arora","year":"2013","unstructured":"Arora A, Mahajan A, Spurden D, et al. Long-term drug survival of TNF inhibitor therapy in RA patients: a systematic review of European national drug registers. Int J Rheumatol. 2013;2013:764518.","journal-title":"Int J Rheumatol"},{"key":"2043_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40259-022-00559-1","volume":"36","author":"JE Gehin","year":"2022","unstructured":"Gehin JE, Goll GL, Brun MK, et al. Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine. BioDrugs. 2022;36:731\u201348.","journal-title":"BioDrugs"},{"key":"2043_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/ecco-jcc\/jjz162","volume":"14","author":"MP Sparrow","year":"2020","unstructured":"Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohns Colitis. 2020;14:542\u201356.","journal-title":"J Crohns Colitis"},{"key":"2043_CR10","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1097\/MIB.0000000000001231","volume":"23","author":"K Papamichael","year":"2017","unstructured":"Papamichael K, Vande Casteele N, Ferrante M, et al. Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window. Inflamm Bowel Dis. 2017;23:1510\u20135.","journal-title":"Inflamm Bowel Dis"},{"key":"2043_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/annrheumdis-2020-216996","volume":"79","author":"E Ulijn","year":"2020","unstructured":"Ulijn E, den Broeder N, Wientjes M, et al. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD. Ann Rheum Dis. 2020;79:867\u201373.","journal-title":"Ann Rheum Dis"},{"key":"2043_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/17425255.2017.1353602","volume":"13","author":"N Van Herwaarden","year":"2017","unstructured":"Van Herwaarden N, Van den Bemt BJF, Wientjes MHM, et al. Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opin Drug Metab Toxicol. 2017;13:843\u201357.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2043_CR13","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/bcp.13192","volume":"83","author":"C Bastida","year":"2017","unstructured":"Bastida C, Ru\u00edz V, Pascal M, et al. Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis? Br J Clin Pharmacol. 2017;83:962\u201375.","journal-title":"Br J Clin Pharmacol"},{"key":"2043_CR14","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","volume":"116","author":"AS Cheifetz","year":"2021","unstructured":"Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol. 2021;116:2014\u201325.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2043_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","volume":"82","author":"CL Krieckaert","year":"2023","unstructured":"Krieckaert CL, van Tubergen A, Gehin JE et al. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023;82(1):65\u201373.","journal-title":"Ann Rheum Dis"},{"key":"2043_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.gastrohep.2024.01.007","volume":"47","author":"F Rodr\u00edguez-Moranta","year":"2024","unstructured":"Rodr\u00edguez-Moranta F, Arg\u00fcelles-Arias F, Hinojosa Del Val J, et al. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis. Gastroenterol Hepatol. 2024;47:522\u201352.","journal-title":"Gastroenterol Hepatol"},{"key":"2043_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10620-018-4917-7","volume":"63","author":"K Papamichael","year":"2018","unstructured":"Papamichael K, Vajravelu RK, Osterman MT, et al. Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease. Dig Dis Sci. 2018;63:761\u20137.","journal-title":"Dig Dis Sci"},{"key":"2043_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31:299\u2013316.","journal-title":"BioDrugs"},{"key":"2043_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","volume":"29","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29:241\u201358.","journal-title":"BioDrugs"},{"key":"2043_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib13010016","volume":"13","author":"T Velikova","year":"2024","unstructured":"Velikova T, Sekulovski M, Peshevska-Sekulovska M. Immunogenicity and loss of effectiveness of biologic therapy for inflammatory bowel disease patients due to anti-drug antibody development. Antibodies (Basel). 2024;13:16.","journal-title":"Antibodies (Basel)"},{"key":"2043_CR21","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u201395.","journal-title":"N Engl J Med"},{"key":"2043_CR22","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/art.39169","volume":"67","author":"M Jani","year":"2015","unstructured":"Jani M, Chinoy H, Warren RB, et al. Biologics in rheumatoid arthritis genetics and genomics study syndicate collaborators. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 2015;67:2011\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"2043_CR23","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","volume":"69","author":"X Roblin","year":"2020","unstructured":"Roblin X, Williet N, Boschetti G, et al. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut. 2020;69:1206\u201312.","journal-title":"Gut"},{"key":"2043_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.16852","volume":"56","author":"X Roblin","year":"2022","unstructured":"Roblin X, Veyrard P, Bastide L, et al. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn\u2019s disease. Aliment Pharmacol Ther. 2022;56:77\u201383.","journal-title":"Aliment Pharmacol Ther"},{"key":"2043_CR25","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s10067-025-07307-0","volume":"44","author":"P Ortiz-Fern\u00e1ndez","year":"2025","unstructured":"Ortiz-Fern\u00e1ndez P, Iniesta-Naval\u00f3n C, Urbieta-Sanz E, et al. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases. Clin Rheumatol. 2025;44:1009\u201318.","journal-title":"Clin Rheumatol"},{"key":"2043_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","volume":"158","author":"A Sazonovs","year":"2020","unstructured":"Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to Infliximab and Adalimumab in patients with Crohn\u2019s disease. Gastroenterology. 2020;158:189\u201399.","journal-title":"Gastroenterology"},{"issue":"8","key":"2043_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4292\/wjgpt.v8.i3.155","volume":"6","author":"MM Kothari","year":"2017","unstructured":"Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. World J Gastrointest Pharmacol Ther. 2017;6(8):155\u201361.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2043_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.crohns.2012.03.018","volume":"7","author":"F Baert","year":"2013","unstructured":"Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn\u2019s patients. J Crohns Colitis. 2013;7:154\u201360.","journal-title":"J Crohns Colitis"},{"key":"2043_CR29","first-page":"30","volume":"522","author":"H Yanai","year":"2015","unstructured":"Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;522:30.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2043_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00384-023-04349-1","volume":"38","author":"J Stallhofer","year":"2023","unstructured":"Stallhofer J, Guse J, Kesselmeier M, et al. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease. Int J Colorectal Dis. 2023;38:54.","journal-title":"Int J Colorectal Dis"},{"key":"2043_CR31","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garc\u00eas","year":"2013","unstructured":"Garc\u00eas S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72:1947\u201355.","journal-title":"Ann Rheum Dis"},{"key":"2043_CR32","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1007\/s10620-024-08515-5","volume":"69","author":"JA Lowell","year":"2024","unstructured":"Lowell JA, Sharma G, Chua V, et al. Reactive immunomodulator addition to infliximab monotherapy restores clinical response in inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2024;69:3920\u201331.","journal-title":"Dig Dis Sci"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02043-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02043-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02043-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:19:00Z","timestamp":1768972740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02043-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2043"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02043-6","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was reviewed and approved by the Clinical Research Ethics Committee of the Hospital General Universitario Reina Sof\u00eda in Murcia (approval number: 10487, date: 10\/06\/2020. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was reviewed and approved by the Ethics Committee of Hospital General Universitario Reina Sof\u00eda (approval code: 5832, approval date: 2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study\n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}